Related Experiment Video
Updated: Jun 3, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic Virus Targeted Therapy for Glioma via Intravenous Delivery
Yechenxing He1,2, Wei Li1, Xiaowei Zhang1
1State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, P. R. China.
Abstract:
Glioma, the deadly primary intracranial tumor, poses challenges in clinical treatment due to its infiltrative growth and resistance to radiation. Oncolytic virus therapy holds potential for the treatment of malignant gliomas, but its application is impeded by the requirement for intracranial injections due to the presence of blood-brain barrier (BBB). In this study, to overcome this limitation, the study develops a nanocapsule encapsulating the recombinant oncolytic virus EV-A71-miR124T, enabling the treatment of glioma through intravenous administration. It is demonstrated that the nanocapsule can cross the BBB and selectively release oncolytic virus at the tumor site, resulting in targeted and specific killing of glioma cells. In mice with implanted intracranial orthotopic gliomas, intravenous administration of the nanocapsule suppresses tumor growth and significantly extends survival time. Consequently, the study establishes an effective treatment method for malignant gliomas using an oncolytic virus nanocapsule through intravenous administration. These findings provide a new strategy for oncolytic virus therapy in glioma treatment and offer perspectives for targeted therapies of other brain tumors and diseases.
Insights
Researchers developed a nanocapsule delivering oncolytic viruses to treat brain gliomas. This intravenous therapy effectively crosses the blood-brain barrier, targeting and destroying tumor cells, and extending survival in mice.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Virology
Background:
- Malignant gliomas are aggressive brain tumors with poor prognosis.
- Current treatments face challenges due to infiltrative growth and blood-brain barrier (BBB) penetration.
- Oncolytic virus therapy shows promise but requires invasive intracranial delivery.
Purpose of the Study:
- To develop an effective intravenous delivery system for oncolytic viruses to treat gliomas.
- To overcome the BBB limitation for brain tumor treatment.
- To evaluate the efficacy of a novel nanocapsule-based oncolytic virus therapy.
Main Methods:
- Development of a nanocapsule encapsulating recombinant oncolytic virus EV-A71-miR124T.
- Demonstration of BBB crossing capability of the nanocapsule.
- Assessment of tumor suppression and survival extension in mice with orthotopic gliomas.
Main Results:
- The nanocapsule successfully crossed the BBB and selectively released the virus at the tumor site.
- Targeted killing of glioma cells was achieved.
- Intravenous administration of the nanocapsule significantly suppressed tumor growth and prolonged survival in mice.
Conclusions:
- An effective intravenous nanocapsule-based oncolytic virus therapy for malignant gliomas was established.
- This approach overcomes BBB limitations for brain tumor treatment.
- The findings offer a new strategy for glioma therapy and potential for other brain diseases.
